Shattuck Labs Advances DR3 Strategy with Extended Runway into 2029

AUSTIN, Texas – November 05, 2026 – In the high-stakes race to conquer inflammatory and immune-mediated diseases, the biotechnology sector has largely coalesced around a single, highly lucrative target: the TL1A ligand. Major pharmaceutical companies have deployed billions of dollars in acquisitions to secure assets in this space. Yet, Shattuck Labs is taking a decidedly contrarian approach. By targeting the DR3 receptor instead of its ligand, the clinical-stage company is betting that a structural pivot can unlock superior efficacy and durability.

Reporting its third-quarter 2026 financial results today, Shattuck Labs outlined a robust clinical trajectory for its lead asset, SL-325, alongside a fortified balance sheet that extends its operational runway into 2029. With mid-stage trials initiating in both Crohn’s disease and hidradenitis suppurativa, the company is positioning itself to challenge the prevailing TL1A narrative.

The Receptor Gambit: Outmaneuvering Pharma Giants

The TL1A/DR3 pathway is a critical mediator in both innate and adaptive immunity, driving inflammation and fibrosis in conditions like inflammatory bowel disease (IBD). The industry's enthusiasm for this pathway is undeniable. Merck’s $10.8 billion acquisition of Prometheus Biosciences for tulisokibart and Roche’s $7.1 billion deal for Telavant’s afimkibart underscore the massive commercial potential of TL1A inhibitors. Sanofi and Teva are also aggressively advancing their co-developed asset, duvakitug.

However, these multi-billion-dollar programs all target the soluble TL1A ligand. Shattuck Labs argues this approach has an inherent flaw: binding free TL1A in the serum can form immune complexes that trigger high rates of anti-drug antibodies (ADAs). High ADA rates can neutralize the drug, leading to treatment resistance and waning efficacy over time. Early studies of some TL1A antibodies have shown ADA incidence rates ranging from 48% to 82%.

Shattuck’s SL-325, a fully human immunoglobulin G monoclonal antibody, targets the DR3 receptor directly. Because DR3 is constitutively expressed on immune cells, it presents a more stable target. By blocking the cell-bound receptor, SL-325 theoretically avoids the formation of immune complexes. Phase 1 data supports this hypothesis, demonstrating a highly favorable immunogenicity profile with an ADA rate of just 3.7%. Furthermore, the durable inhibition of TL1A binding to DR3 may enable quarterly maintenance dosing, a significant convenience advantage over more frequently administered biologics.

“We are very excited to begin Phase 2 clinical development with SL-325 in both Crohn’s disease and hidradenitis suppurativa,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “We believe these two studies will allow direct comparisons with the TL1A antibody class and evaluate the efficacy that may be left on the table due to the potential immunogenicity liabilities of TL1A antibodies.”

To test this, Shattuck has initiated the RECEPTIVE-CD1 Phase 2b clinical trial. The randomized, double-blind, placebo-controlled study will evaluate three dose levels of SL-325 in approximately 232 patients with moderately-to-severely active Crohn's disease. The primary endpoint is endoscopic response at 12 weeks, a rigorous benchmark that regulators increasingly demand to prove true disease modification. Data from the induction portion of the trial is expected in the first half of 2028.

Beyond the Gut: Hidradenitis Suppurativa as the Next Battleground

While IBD remains the primary proving ground for TL1A/DR3 interventions, Shattuck is aggressively expanding its footprint into dermatology. The company announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa (HS) in the fourth quarter of 2026, following an Investigational New Drug (IND) application submitted in October.

HS is a chronic, intensely painful inflammatory skin disease characterized by nodules, abscesses, and severe scarring. The condition has historically suffered from a lack of targeted therapies, but it is rapidly emerging as a major focus for immunologists. The RECEPTIVE-HS1 trial will enroll approximately 150 patients to evaluate two dose levels of SL-325 against a placebo. The primary endpoint is the Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16, with data also expected in the first half of 2028.

To navigate the complex regulatory and clinical landscape of HS, Shattuck has made a highly strategic leadership hire, appointing Dr. Shoba Ravichandran as Senior Vice President of Clinical Development. Dr. Ravichandran brings over two decades of drug development experience, most notably from Novartis, where she spearheaded the global approval of Cosentyx (secukinumab) for HS. Her direct experience in securing FDA approval for a novel HS therapeutic, coupled with her deep understanding of trial design and endpoints like HiSCR50, provides Shattuck with an invaluable strategic edge as it enters this crowded space.

Shattuck’s ambitions in autoimmune diseases extend beyond SL-325. The company also presented compelling preclinical data at UEG Week 2026 for SL-846, a potentially first-in-class bispecific antibody that blocks both DR3 and the IL-23 receptor (IL-23R). Data from a GLP toxicology study in non-human primates showed the drug was well-tolerated at high doses, achieved complete blockade of both pathways, and exhibited no evidence of receptor agonism. Crucially, the non-human primate data supports the potential for quarterly subcutaneous dosing in humans, with a projected human ADA rate of between 8% and 12%. Shattuck expects to initiate a Phase 1 clinical trial of SL-846 in healthy volunteers and report initial data in 2027.

Funded Through 2029: Building a Multi-Year Runway

Executing concurrent mid-stage clinical trials across multiple indications requires substantial capital, a reality that often forces clinical-stage biotechs into dilutive financing arrangements under unfavorable market conditions. Shattuck Labs, however, appears to have insulated itself against this vulnerability.

As of September 30, 2026, the company reported cash, cash equivalents, and short-term investments of $196.3 million, a dramatic increase from the $86.1 million reported at the same time in 2025. This fortified balance sheet provides Shattuck with a projected financial runway into 2029.

The capital buffer is critical given the company's accelerating burn rate. Research and development expenses surged to $21.6 million in the third quarter of 2026, up from $7.6 million in the prior-year period, directly reflecting the costs associated with ramping up the RECEPTIVE-CD1 and RECEPTIVE-HS1 trials. General and administrative expenses also crept up to $5.5 million, contributing to a quarterly net loss of $25.2 million, or $0.14 per share.

Despite the widening net loss, the strategic value of Shattuck's cash position cannot be overstated. Securing a runway that stretches past pivotal Phase 2 readouts is a luxury in today's biotech market, allowing the science to mature without the constant overhang of capital raises. By funding operations through the anticipated first-half 2028 data readouts for both Crohn's disease and HS, Shattuck has ensured that its management team can negotiate from a position of strength should the clinical data validate their contrarian approach to the DR3 pathway.